Novavax Advances Development of Novel COVID-19 Vaccine
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: GlobeNewswire
Vaccine candidate derived from coronavirus spike (S) proteinMatrix-M™ adjuvant expected to boost immune responsesPhase 1 clinical trial planned for late spring GAITHERSBURG, Md., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its efforts to develop a novel vaccine to protect against coronavirus disease COVID-19. Novavax has produced and is currently assessing multiple nanoparticle vaccine candidates in animal models prior to identifying an optimal candidate for human testing, which is expected to begin by the end of spring 2020. Novavax created the COVID-19 vaccine candidates using its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. Novavax expects to utilize its proprietary Matrix-M™ adjuvant with its COVID-19 vaccine candidate to enhance immune re
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- RSV Vaccine Market To Reach USD 2.2 Billion By 2032 | DataHorizzon Research [Yahoo! Finance]Yahoo! Finance
- Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action SettlementAccesswire
- Hedge fund Shah Capital recommends two new candidates for Novavax board [Reuters]Reuters
NVAX
Earnings
- 2/28/24 - Miss
NVAX
Sec Filings
- 4/26/24 - Form 8-K
- 4/15/24 - Form SC
- 4/15/24 - Form SC
- NVAX's page on the SEC website